Denosumab is a monoclonal antibody used for the treatment of:
**Core Concept**
Denosumab is a human monoclonal antibody that targets RANKL (Receptor Activator of Nuclear factor Kappa-Β Ligand), a protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. By inhibiting RANKL, denosumab reduces osteoclast activity and subsequent bone loss.
**Why the Correct Answer is Right**
Denosumab is used in the treatment of conditions characterized by excessive bone resorption, such as osteoporosis, bone metastases associated with malignancies, and giant cell tumor of bone. The mechanism of action involves the inhibition of RANKL binding to its receptor, RANK, expressed on the surface of osteoclasts and their precursors, leading to a decrease in osteoclast activity and bone resorption. This results in an increase in bone mineral density and a reduction in the risk of fractures.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because denosumab is not primarily used for the treatment of rheumatoid arthritis, although it may be used in the treatment of bone-related complications in this condition.
**Option B:** This option is incorrect because denosumab is not used for the treatment of multiple myeloma, although it may be used in the treatment of bone-related complications in this condition.
**Option C:** This option is incorrect because denosumab is not used for the treatment of inflammatory bowel disease.
**Clinical Pearl / High-Yield Fact**
Denosumab is contraindicated in patients with a history of hypersensitivity to denosumab or any of its components. Additionally, patients with a history of atypical femoral fractures or osteonecrosis of the jaw should be carefully evaluated before starting denosumab treatment.
**Correct Answer: C. Giant cell tumor of bone.